(1′S)-Acetoxychavicol acetate and its enantiomer inhibit tumor cells proliferation via different mechanisms

Chemico-Biological Interactions

Volumn 172, Issue 3, 2008, Pages 216-223

  Xu, Shenghui ^a   Kojima Yuasa, Akiko ^a   Azuma, Hideki ^a   Huang, Xuedan ^a   Norikura, Toshio ^a   Kennedy, David Opare ^a   Matsui Yuasa, Isao ^a  

^a Osaka Prefecture University   (Japan)

Author keywords

1 Acetoxychavicol acetate; Cell cycle; Ehrlich ascites tumor cells; Enantiomer; p27kip1; Retinoblastoma protein (Rb) phosphorylation

Indexed keywords

ACETOXYCHAVICOL ACETATE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; 1' ACETOXYCHAVICOL ACETATE; 1'-ACETOXYCHAVICOL ACETATE; TERPENE;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; EHRLICH ASCITES TUMOR CELL; ENANTIOMER; ESTERIFICATION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; ANIMAL; CELL CULTURE; DRUG EFFECT; EHRLICH ASCITES TUMOR; METABOLISM; PHOSPHORYLATION; STEREOISOMERISM; TIME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, EHRLICH TUMOR; CELL PROLIFERATION; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; STEREOISOMERISM; TERPENES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 40949089710     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.01.002     Document Type: Article

References (41)

1. Murakami A., Ohura S., Nakamura Y., Koshimizu K., and Ohigashi H. 1′-Acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin. Oncology 53 5 (1996) 386-391
2. Ohnishi M., Tanaka T., Makita H., Kawamori T., Mori H., Satoh K., Hara A., Murakami A., Ohigashi H., and Koshimizu K. Chemopreventive effect of a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate, on rat oral carcinogenesis. Jpn. J. Cancer Res. 87 4 (1996) 349-356
3. Tanaka T., Makita H., Kawamori T., Kawabata K., Mori H., Murakami A., Satoh K., Hara A., Ohigashi H., and Koshimizu K. A xanthine oxidase inhibitor 1′-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis 18 5 (1997) 1113-1118
4. Kawabata K., Tanaka T., Yamamoto T., Ushida J., Hara A., Murakami A., Koshimizu K., Ohigashi H., Stoner G.D., and Mori H. Suppression of N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis by dietary feeding of 1′-acetoxychavicol acetate. Jpn. J. Cancer Res. 91 2 (2000) 148-155
5. Miyauchi M., Nishikawa A., Furukawa F., Nakamura H., Son H.Y., Murakami A., Koshimizu K., Ohigashi H., and Hirose M. Inhibitory effects of 1′-acetoxychavicol acetate on N-nitrosobis(2-oxopropyl)-amine-induced initiation of cholangiocarcinogenesis in Syrian hamsters. Jpn. J. Cancer Res. 91 5 (2000) 477-481
6. Moffatt J., Hashimoto M., Kojima A., Kennedy D.O., Murakami A., Koshimizu K., Ohigashi H., and Matsui-Yuasa I. Apoptosis induced by 1′-acetoxychavicol acetate in Ehrlich ascites tumor cells is associated with modulation of polyamine metabolism and caspase-3 activation. Carcinogenesis 21 12 (2000) 2151-2157
7. Ohnishi H., Asamoto M., Tujimura K., Hokaiwado N., Takahashi S., Ogawa K., Kuribayashi M., Ogiso T., Okuyama H., and Shirai T. Inhibition of cell proliferation by nobiletin, a dietary phytochemical, associated with apoptosis and characteristic gene expression, but lack of effect on early rat hepatocarcinogenesis in vivo. Cancer Sci. 95 12 (2004) 936-942
8. Zheng Q., Hirose Y., Yoshimi N., Murakami A., Koshimizu K., Ohigashi H., Sakata K., Matsumoto Y., Sayama Y., and Mori H. Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. J. Cancer Res. Clin. Oncol. 128 10 (2002) 539-546
9. Ito K., Nakazato T., Murakami A., Yamato K., Miyakawa Y., Yamada T., Hozumi N., Ohigashi H., Ikeda Y., and Kizaki M. Induction of apoptosis in human myeloid leukemic cells by 1′-acetoxychavicol acetate through a mitochondrial- and Fas-mediated dual mechanism. Clin. Cancer Res. 10 6 (2004) 2120-2130
10. Moffatt J., Kennedy D.O., Kojima A., Hasuma T., Yano Y., Otani S., Murakami A., Koshimizu K., Ohigashi H., and Matsui-Yuasa I. Involvement of protein tyrosine phosphorylation and reduction of cellular sulfhydryl groups in cell death induced by 1′-acetoxychavicol acetate in Ehrlich ascites tumor cells. Chem. Biol. Interact. 139 2 (2002) 215-230
11. Unahara Y., Kojima-Yuasa A., Higashida M., Kennedy D.O., Murakami A., Ohigashi H., and Matsui-Yuasa I. Cellular thiol status-dependent inhibition of tumor cell growth via modulation of p27(kip1) translocation and retinoblastoma protein phosphorylation by 1′-acetoxychavicol acetate. Amino Acids 33 3 (2007) 469-476
12. Matsui-Yuasa I., Kojima-Yuasa A., and Kennedy D.O. 1′-Acetoxychavicol acetate induces an inhibition of tumor cell growth via a rapid and drastic modulation of glutathione metabolism. FASEB J. (2006) A565-A566
13. Lee S., and Ando T. Optically active 1′-acetoxychavicol acetate and its positional isomers:synthesis and repellent effect against Azuki Bean Weevil. J. Pestic. Sci. 26 (2001) 76-81
14. Matsuda H., Ando S., Morikawa T., Kataoka S., and Yoshikawa M. Structure-activity relationships of 1′S-1′-acetoxychavicol acetate for inhibitory effect on NO production in lipopolysaccharide-activated mouse peritoneal macrophages. Bioorg. Med. Chem. Lett. 15 7 (2005) 1949-1953
15. Azuma H., Miyasaka K., Yokotani T., Tachibana T., Kojima-Yuasa A., Matsui-Yuasa I., and Ogino K. Lipase-catalyzed preparation of optically active 1′-acetoxychavicol acetates and their structure-activity relationships in apoptotic activity against human leukemia HL-60 cells. Bioorg. Med. Chem. 14 6 (2006) 1811-1818
16. Ko S.Y., Lin S.C., Chang K.W., Liu C.J., Chang S.S., Lu S.Y., and Liu T.Y. Modulation of KGF-1 gene expression in oral fibroblasts by ripe areca nut extract. J. Oral Pathol. Med. 32 7 (2003) 399-407
17. Hsu S.M., and Soban E. Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J. Histochem. Cytochem. 30 10 (1982) 1079-1082
18. Kennedy D.O., Kojima A., Moffatt J., Yamagiwa H., Yano Y., Hasuma T., Otani S., and Matsui-Yuasa I. Cellular thiol status-dependent inhibition of tumor cell growth via modulation of retinoblastoma protein phosphorylation by (-)-epigallocatechin. Cancer Lett. 179 1 (2002) 25-32
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
20. Hengst L., and Reed S.I. Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunol. 227 (1998) 25-41
21. Sherr C.J., and Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9 10 (1995) 1149-1163
22. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 12 (1999) 1501-1512
23. Paggi M.G., Baldi A., Bonetto F., and Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. J. Cell. Biochem. 62 3 (1996) 418-430
24. Wang J.Y., Knudsen E.S., and Welch P.J. The retinoblastoma tumor suppressor protein. Adv. Cancer Res. 64 (1994) 25-85
25. Hiebert S.W. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol. Cell. Biol. 13 6 (1993) 3384-3391
26. Qian Y., Luckey C., Horton L., Esser M., and Templeton D.J. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol. Cell. Biol. 12 12 (1992) 5363-5372
27. Qin X.Q., Chittenden T., Livingston D.M., and Kaelin Jr. W.G. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6 6 (1992) 953-964
28. Morgan D.O. Principles of CDK regulation. Nature 374 6518 (1995) 131-134
29. Sherr C.J. Cancer cell cycles. Science 274 5293 (1996) 1672-1677
30. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yew P.R., Draetta G.F., and Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269 5224 (1995) 682-685
31. Feldman R.M., Correll C.C., Kaplan K.B., and Deshaies R.J. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91 2 (1997) 221-230
32. Skowyra D., Craig K.L., Tyers M., Elledge S.J., and Harper J.W. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91 2 (1997) 209-219
33. Carrano A.C., Eytan E., Hershko A., and Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell. Biol. 1 4 (1999) 193-199
34. Sutterluty H., Chatelain E., Marti A., Wirbelauer C., Senften M., Muller U., and Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat. Cell. Biol. 1 4 (1999) 207-214
35. Tsvetkov L.M., Yeh K.H., Lee S.J., Sun H., and Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 9 12 (1999) 661-664
36. Demerson C.A., Humber L.G., Abraham N.A., Schilling G., Martel R.R., and Pace-Asciak C. Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J. Med. Chem. 26 12 (1983) 1778-1780
37. Brocks D.R., and Jamali F. Etodolac clinical pharmacokinetics. Clin. Pharmacokinet. 26 4 (1994) 259-274
38. Hedvat M., Jain A., Carson D.A., Leoni L.M., Huang G., Holden S., Lu D., Corr M., Fox W., and Agus D.B. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell 5 6 (2004) 565-574
39. Martelli M.L., Iuliano R., Le Pera I., Sama I., Monaco C., Cammarota S., Kroll T., Chiariotti L., Santoro M., and Fusco A. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab. 87 10 (2002) 4728-4735
40. Ohta K., Endo T., Haraguchi K., Hershman J.M., and Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 86 5 (2001) 2170-2177
41. Hupfeld C.J., and Weiss R.H. TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am. J. Physiol. Endocrinol. Metab. 281 2 (2001) E207-E216